Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Revolution Medicines, Inc. NASDAQ:RVMD | $37.26B | $172.29 | Not rated | -23.3 | +126.44% |
Tango Therapeutics, Inc. NASDAQ:TNGX | $4.32B | $25.50 | Not rated | -38.9 | +173.63% |
IDEAYA Biosciences, Inc. NASDAQ:IDYA | $3.08B | $31.83 | Not rated | -19.5 | -21.42% |
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -21.25% |
Verastem, Inc. NASDAQ:VSTM | $1.03B | $8.18 | Not rated | -2.1 | -25.89% |
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | $814.71M | $7.86 | Not rated | -6.7 | -35.71% |
Kura Oncology, Inc. NASDAQ:KURA | $713.90M | $7.77 | Not rated | -2.9 | -33.75% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -46.07% |
Continue the stock analysis
Jump to another research area for this company.